GnRH类似物对子宫内膜受体性的影响:一项全面的研究
Zhuqiang He1, Na Guo2, Yangcheng Yao3
1Department of Neurosurgery, Wuhan First Hospital, Wuhan, China.
Journal of assisted reproduction and genetics
|May 10, 2025
概括
在试管婴儿中使用的激素释放激素 (GnRH) 类似物不会显著改变子宫内膜受容性的关键标志物. 然而,GnRH抗剂可能会对植入潜力产生负面影响,需要进一步调查.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 在体外受精 (IVF)
- 分子生物学分子生物学
背景情况:
- 子宫内膜受容性对于成功怀孕至关重要.
- 激素释放激素 (GnRH) 的类似物在试管婴儿中很常见,但它们对子宫内膜的影响尚不清楚.
研究的目的:
- 通过体外模型研究GnRH类似物对子宫内膜受容性的影响.
- 评估GnRH模拟对 trofhoblast粘附和子宫内膜受容性标记物的作用.
主要方法:
- 在子宫内膜样本中分析GnRH受体 (GnRHR) 表达.
- 构建一个3D子宫内膜模型,以评估热囊细胞粘附.
- 评估基因和蛋白质表达的变化,以响应GnRH类似物.
主要成果:
- 在分泌阶段上皮质中,GnRHR的表达更高.
- 没有观察到热囊细胞粘附或初级受体性标记物的显著变化.
- 蛋白质组分析显示ITGAE对抗剂下调和FAAH2对抗剂上调.
结论:
- 在试管婴儿度下,GnRH类似物不会显著影响一次性子宫内膜受容性标志物.
- GnRH抗剂可能会对子宫内膜受体产生不利影响.
- 需要进一步的研究来了解GnRH类似物对试管婴儿结果的间接影响.
相关概念视频
Hormonal Regulation of the Menstrual Cycle
195
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
195
Hormonal Control of the Ovarian Cycle
324
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
324
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
194
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
194
Internal Receptors
68.5K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
68.5K
Glucagon-like Receptor Agonists
266
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
266
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
176
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
176


